We are live on
!
Find out more
FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$237M
1-Year Est. Return
107.53%
This Fund
S&P 500
This Quarter
Est. Return
-16.3%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$740M
AUM Growth
-$95M
(-11%)
Cap. Flow
+$58.7M
Cap. Flow
% of AUM
7.93%
Top 10 Holdings %
Top 10 Hldgs %
98.31%
Holding
16
New
3
Increased
–
Reduced
4
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lyell Immunopharma
LYEL
|
+$218M |
| 2 |
Quantum-Si Incorporated
QSI
|
+$46.8M |
| 3 |
Tempest Therapeutics
TPST
|
+$3.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Keros Therapeutics
KROS
|
+$85.1M |
| 2 |
ALX Oncology
ALXO
|
+$58M |
| 3 |
Relay Therapeutics
RLAY
|
+$52.2M |
| 4 |
Cytokinetics
CYTK
|
+$7.91M |
| 5 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
+$3.68M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KNTE
1
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $225M | 30.43% |
9,671,643
| – | – |
|
|
2
Lyell Immunopharma
LYEL
$317M
| $216M | 29.16% |
+664,109
| New | +$218M |
|
3
Pharvaris
PHVS
$2.28B
| $60.8M | 8.21% |
3,261,926
| – | – |
|
4
Aclaris Therapeutics
ACRS
$726M
| $59.7M | 8.07% |
3,399,034
| – | – |
|
|
5
Quantum-Si Incorporated
QSI
$155M
| $54.7M | 7.4% |
+4,463,619
| New | +$46.8M |
|
6
Kura Oncology
KURA
$800M
| $38.6M | 5.21% |
1,849,947
| – | – |
|
7
Nurix Therapeutics
NRIX
$2.41B
| $32M | 4.32% |
1,205,798
-32,658
| -3% | -$959K |
|
|
8
Relay Therapeutics
RLAY
$4.1B
| $20.4M | 2.75% |
556,380
-1,583,000
| -74% | -$52.2M |
|
|
9
Cytokinetics
CYTK
$10.5B
| $10.8M | 1.46% |
545,101
-336,800
| -38% | -$7.91M |
|
10
Olema Pharmaceuticals
OLMA
$1B
| $9.57M | 1.29% |
342,030
-51,000
| -13% | -$1.45M |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $7.79M | 1.05% |
1,787,094
| – | – |
|
|
DBTX
12
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $2.56M | 0.35% |
297,711
| – | – |
|
|
13
Tempest Therapeutics
TPST
$13.7M
| $2.13M | 0.29% |
+14,632
| New | +$3.29M |
|
|
14
ALX Oncology
ALXO
$261M
| – | – |
-785,945
| Closed | -$58M |
|
|
15
Keros Therapeutics
KROS
$199M
| – | – |
-1,382,641
| Closed | -$85.1M |
|
|
PNT
16
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| – | – |
-350,000
| Closed | -$3.68M |
|
Similar funds
BCM
AG
FL
PVM
MFA
TCM
WW
CB
Foresite Capital Management IV's Q2 2021 Portfolio in Review
As of Q2 2021, Foresite Capital Management IV held 16 positions worth $740M, down 11% from $835M the previous quarter. Its ten largest holdings account for 98% of the portfolio.
Foresite Capital Management IV deployed $58.7M of net new capital in Q2 2021, opening 3 new positions. Its largest new stake was Lyell Immunopharma: 664,109 shares worth $216M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Relay Therapeutics, an estimated $52.2M trimmed.
- Foresite Capital Management IV's largest Q2 2021 buy was Lyell Immunopharma: 664,109 shares worth $216M.
- Foresite Capital Management IV's biggest Q2 2021 reduction was Relay Therapeutics, cutting an estimated $52.2M.
- Foresite Capital Management IV fully exited Keros Therapeutics in Q2 2021, selling an estimated $85.1M.
- Foresite Capital Management IV's ten largest holdings make up 98% of its $740M portfolio in Q2 2021.
- Foresite Capital Management IV opened 3 new positions and closed 3 in Q2 2021.
- Foresite Capital Management IV's portfolio value fell 11% quarter-over-quarter to $740M.
Based on Foresite Capital Management IV's 13F filing for Q2 2021, filed 16 Aug 2021.